Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service.


Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
2019
Historique:
entrez: 26 5 2019
pubmed: 28 5 2019
medline: 18 12 2019
Statut: ppublish

Résumé

Neuromuscular disorders (NMDs) are clinically and genetically heterogeneous. Accurate molecular genetic diagnosis can improve clinical management, provides appropriate genetic counseling and testing of relatives, and allows potential therapeutic trials. To establish the clinical utility of panel-based whole exome sequencing (WES) in NMDs in a population with children and adults with various neuromuscular symptoms. Clinical exome sequencing, followed by diagnostic interpretation of variants in genes associated with NMDs, was performed in a cohort of 396 patients suspected of having a genetic cause with a variable age of onset, neuromuscular phenotype, and inheritance pattern. Many had previously undergone targeted gene testing without results. Disease-causing variants were identified in 75/396 patients (19%), with variants in the three COL6-genes (COL6A1, COL6A2 and COL6A3) as the most common cause of the identified muscle disorder, followed by variants in the RYR1 gene. Together, these four genes account for almost 25% of cases in whom a definite genetic cause was identified. Furthermore, likely pathogenic variants and/or variants of uncertain significance were identified in 95 of the patients (24%), in whom functional and/or segregation analysis should be used to confirm or reject the pathogenicity. In 18% of the cases with a disease-causing variant of which we received additional clinical information, we identified a genetic cause in genes of which the associated phenotypes did not match that of the patients. Hence, the advantage of panel-based WES is its unbiased approach. Whole exome sequencing, followed by filtering for NMD genes, offers an unbiased approach for the genetic diagnostics of NMD patients. This approach could be used as a first-tier test in neuromuscular disorders with a high suspicion of a genetic cause. With uncertain results, functional testing and segregation analysis are needed to complete the evidence.

Sections du résumé

BACKGROUND BACKGROUND
Neuromuscular disorders (NMDs) are clinically and genetically heterogeneous. Accurate molecular genetic diagnosis can improve clinical management, provides appropriate genetic counseling and testing of relatives, and allows potential therapeutic trials.
OBJECTIVE OBJECTIVE
To establish the clinical utility of panel-based whole exome sequencing (WES) in NMDs in a population with children and adults with various neuromuscular symptoms.
METHODS METHODS
Clinical exome sequencing, followed by diagnostic interpretation of variants in genes associated with NMDs, was performed in a cohort of 396 patients suspected of having a genetic cause with a variable age of onset, neuromuscular phenotype, and inheritance pattern. Many had previously undergone targeted gene testing without results.
RESULTS RESULTS
Disease-causing variants were identified in 75/396 patients (19%), with variants in the three COL6-genes (COL6A1, COL6A2 and COL6A3) as the most common cause of the identified muscle disorder, followed by variants in the RYR1 gene. Together, these four genes account for almost 25% of cases in whom a definite genetic cause was identified. Furthermore, likely pathogenic variants and/or variants of uncertain significance were identified in 95 of the patients (24%), in whom functional and/or segregation analysis should be used to confirm or reject the pathogenicity. In 18% of the cases with a disease-causing variant of which we received additional clinical information, we identified a genetic cause in genes of which the associated phenotypes did not match that of the patients. Hence, the advantage of panel-based WES is its unbiased approach.
CONCLUSION CONCLUSIONS
Whole exome sequencing, followed by filtering for NMD genes, offers an unbiased approach for the genetic diagnostics of NMD patients. This approach could be used as a first-tier test in neuromuscular disorders with a high suspicion of a genetic cause. With uncertain results, functional testing and segregation analysis are needed to complete the evidence.

Identifiants

pubmed: 31127727
pii: JND180376
doi: 10.3233/JND-180376
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-258

Auteurs

Dineke Westra (D)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Meyke I Schouten (MI)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Bas C Stunnenberg (BC)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.

Benno Kusters (B)

Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Christiaan G J Saris (CGJ)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.

Corrie E Erasmus (CE)

Department of Pediatric Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.

Baziel G van Engelen (BG)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.

Saskia Bulk (S)

Service de Génétique Humaine, CHU de Liège, Liège, Belgium.

Corien C Verschuuren-Bemelmans (CC)

Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.

E H Gerkes (EH)

Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.

Christa de Geus (C)

Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.

P A van der Zwaag (PA)

Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands.

Sophelia Chan (S)

Department of Pediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.

Brian Chung (B)

Department of Pediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.

Daniela Q C M Barge-Schaapveld (DQCM)

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Marjolein Kriek (M)

Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.

Yves Sznajer (Y)

Center de Génétique Humaine, Clinique Universitaires Saint Luc, Bruxelles, Belgium.

Karin van Spaendonck-Zwarts (K)

Department of Clinical Genetics, Amsterdam University Medical Centre, Amsterdam, The Netherlands.

Anneke J van der Kooi (AJ)

Department of Neurology, Amsterdam Medical Center, Amsterdam UMC, University of Amsterdam, Neuroscience institute, Amsterdam, The Netherlands.

Amanda Krause (A)

Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, The University of the Witwatersrand, Johannesburg, South Africa.

Bitten Schönewolf-Greulich (B)

Department of Clinical Genetics, Rigshospitalet Copenhagen, Denmark.

Christine de Die-Smulders (C)

Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.

Suzanne C E H Sallevelt (SCEH)

Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.

Ingrid P C Krapels (IPC)

Department of Clinical Genetics, Maastricht University Medical Center+, Maastricht, The Netherlands.

Magnhild Rasmussen (M)

Department of Child Neurology and Unit for Congenital and Inherited Neuromuscular Disorders, Oslo University Hospital, Oslo, Norway.

Isabelle Maystadt (I)

Center de Génétique Humaine, Institut de Pathologie et de Génétique, Gosselies, Belgium.

Anneke J A Kievit (AJA)

Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.

Nanna Witting (N)

Department of Neurology, Rigshospitalet, Copenhagen, Denmark.

Maartje Pennings (M)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Rowdy Meijer (R)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Christian Gillissen (C)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Erik-Jan Kamsteeg (EJ)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Nicol C Voermans (NC)

Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH